Ann: Quarterly Update and Appendix 4C, page-19

NanoDx has talked up the test product and it's potential but has essentially failed at even entering the game (possibly multiple times at this point). EUAs are granted every day for firms both smaller and larger than NanoDx and eventually the door will close. I understand that the NanoDx test's features may be hugely beneficial but is the company capable of delivering?

I believe that we at least deserve to know what 'challenges' are now being faced. Does the issue still lie with the cartridge or has that been resolved and there is now something else? Providing clarity on this could be all the difference. I think the market's reaction so far is just.